Category: PRen

---

Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

By Zhizi Zhao, 12th December 2017

Clementia Announces Date of Corporate Update Conference Call

By Zhizi Zhao, 5th December 2017

Clementia Reports Third Quarter 2017 Financial Results and Business Highlights

By Zhizi Zhao, 13th November 2017

Clementia Pharmaceuticals to Participate in Upcoming Investor Conferences

By Zhizi Zhao, 6th September 2017

Clementia Announces Data Presentations at Upcoming Medical Conferences in September

By Zhizi Zhao, 31st August 2017

Clementia Announces Closing of Over-Allotment Option in its Initial Public Offering

By Zhizi Zhao, 21st August 2017

Clementia Announces Pricing of Initial Public Offering

By Zhizi Zhao, 8th April 2017

Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends

By Zhizi Zhao, 28th March 2017

Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva

By Zhizi Zhao, 14th October 2016

Positive Effects of Palovarotene on Spontaneous Heterotopic Ossification, Mobility, and Skeletal Growth in Mouse Models of FOP Reported in Journal of Bone and Mineral Research

By Zhizi Zhao, 14th April 2016

• Newer
• 1
• 2
• 3
• 4
• 5
• 6
• Older